Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Outlines Priorities For Next Five Years In Strategic Report

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency identifies four overarching priorities: advancing regulatory science and innovation; strengthening the global supply chain; strengthening compliance and enforcement activities; and addressing unmet public health needs.

You may also be interested in...



FDA Budget Issues Creep Into Strategic Priorities

“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.

FDA Biomedical Innovation Initiative Draws On Familiar Themes

FDA Biomedical Innovation Initiative Draws On Familiar Themes

Related Content

Topics

UsernamePublicRestriction

Register

PS071385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel